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DRUG EVALUATION
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James F. Howard Jr.a, John Vissingb, Nils E. Gilhusc, M. Isabel Leited, Kimiaki Utsugisawae, Petra W. Dudaf, 
Ramin Farzaneh-Farf, Hiroyuki Muraig and Heinz Wiendlh
aDepartment of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; bDepartment of Clinical Medicine, Rigshospitalet, 
University of Copenhagen, Copenhagen, Denmark; cDepartment of Clinical Medicine, University of Bergen and Haukeland University Hospital, 
Bergen, Norway; dNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; eDepartment of Neurology, Hanamaki General 
Hospital, Hanamaki, Iwate, Japan; fUCB Pharma, Cambridge, MA, USA; gDepartment of Neurology, International University of Health and Welfare, 
Narita, Chiba, Japan; hDepartment of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany
ABSTRACT
Introduction: Generalized myasthenia gravis (gMG) is an autoimmune disorder in which pathogenic 
autoantibodies damage the neuromuscular junction, causing disabling or life-threatening muscle 
weakness. Most treatments nonspecifically inhibit aspects of the immune system, do not directly 
address the causal mechanisms of tissue damage, and often have side-effect profiles that negatively 
impact patients. Understanding of the central pathogenic role of the complement cascade in gMG is 
advancing, and a new complement-targeting treatment is under investigation.
Areas covered: We provide an overview of gMG etiology, the complement cascade, current treatments, 
and the investigational gMG therapy zilucoplan. Zilucoplan is a small, subcutaneously administered, 
macrocyclic peptide that inhibits cleavage of complement component C5 and the subsequent forma-
tion of the membrane attack complex.
Expert opinion: In a randomized, double-blind, placebo-controlled, phase 2 clinical trial, zilucoplan 
demonstrated clinically meaningful complement inhibition in patients with acetylcholine receptor- 
positive gMG. Zilucoplan, a first-of-its-kind cyclic peptide targeting C5, appears to be a therapeutic 
option for the treatment of gMG based on available pharmacokinetic/pharmacodynamic data and 
phase 1 and 2 efficacy, safety, and tolerability data with limited long-term follow-up. Zilucoplan use 
earlier in the treatment paradigm would be suitable in this population should phase 3 efficacy and 
safety data be equally favorable.
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1. Introduction
1.1. Generalized Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease characterized 
by chronic generalized or localized muscle weakness that is 
worsened by exercise or repetitive muscle use [1]. The preva-
lence of MG varies globally from an estimated 15 to 179 -
per million people [2]. Ocular weakness (eg, ptosis and 
diplopia) is the first presenting symptom in up to 86% of cases, 
and 80% of these patients will progress to generalized MG (gMG) 
[3,4]. Although the disease course varies, most patients with gMG 
reach maximum disease severity within 1 to 2 years of symptom 
onset with no further progression thereafter [3,5].
The symptoms of gMG impair daily functioning and the 
work, leisure, and social activities of most patients, leading to 
reduced income, emotional burden, frequent use of health-
care resources, and a decreased quality of life (QoL) [6–11]. 
Prolonged muscle weakness can potentially increase the risk 
of obesity, osteoporosis, and respiratory infections [12]. At 
some point in the evolution of their disease, approximately 
20% of patients experience respiratory muscle weakness that 
progresses to a life-threatening state known as myasthenic 
crisis [5,6,13]. In addition to gMG disease burdens, patients 
must frequently navigate comorbidities such as thymic malig-
nancies and related conditions; other autoimmune diseases 
such as thyroid disease, pernicious anemia, systemic lupus 
erythematosus, rheumatoid arthritis, neuromyelitis optica 
spectrum disorder, and inflammatory myopathies; and toxici-
ties associated with long-term use of corticosteroids and 
immunosuppressants [14–19].
Normal neuromuscular transmission is mediated by the bind-
ing of presynaptic acetylcholine to acetylcholine receptors (AChRs) 
in the postsynaptic membrane of the neuromuscular junction 
(NMJ). In MG, this transmission is impaired by autoantibodies 
that bind to AChRs or to functionally related molecules [1]. Anti- 
AChR antibodies are present in 80% to 88% of patients with MG, 
and contribute to early-onset (i.e., prior to 50 years of age), late- 
onset (i.e., ≥50 years), thymoma-associated, and ocular MG disease 
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subtypes [5,20,21]. A smaller proportion of patients (<10%) harbor 
autoantibodies against muscle-specific kinase (MuSK) or lipopro-
tein-related protein 4 or are seronegative for all three autoantibo-
dies [22–25]. The differences in MG antibody subtype have a major 
impact on treatment decisions [12]. This article focuses primarily 
on patients with anti-AChR antibody-positive (AChR+) gMG.
A key mechanism of signal impairment in gMG involves the 
anti-AChR antibody-mediated activation of the complement cas-
cade, which has been shown to induce architectural changes to 
the postsynaptic membrane [5,26,27]. Detailed evidence for the 
role of complement in MG in humans and animal models has been 
recently reviewed [28,29]. Other anti-AChR antibody-mediated 
mechanisms of signal impairment include functional AChR block-
ade and the process of receptor cross-linking, internalization, and 
degradation (i.e., antigenic modulation) [5,30,31].
1.2. The Terminal Complement Cascade
Complement-mediated destruction of the NMJ, initiated by the 
presence of pathogenic autoantibodies, is a major cause of MG 
pathology [26,28,32,33]. The complement cascade is a critical 
part of the immune system that is initiated by any one of three 
separate pathways (alternative, classical, and lectin; Figure 1A). 
All three pathways first converge at complement component 3 
(C3), with a second convergence point at C5. C5 is cleaved to 
produce C5a and C5b, with subsequent recruitment of C6, C7, C8, 
and C9 to yield the pore-like terminal complement complex C5b- 
9, also known as the membrane attack complex (MAC) [32,34]. 
Accumulation of the MAC on the postsynaptic plasma mem-
brane of the NMJ mediates tissue damage and destruction of 
the delicate cytoarchitecture and electrochemical integrity of the 
postsynaptic membrane (Figure 1B) [27,32]. The complement 
cascade is implicated as a key mediator of cell and tissue damage 
in numerous other inflammatory and autoimmune disorders 
including immune-mediated necrotizing myopathies [35], parox-
ysmal nocturnal hemoglobinuria [36], neuromyelitis optica [37], 
and atypical hemolytic uremic syndrome [38]. It has been 
hypothesized that complement and inflammation also play 
a role in amyotrophic lateral sclerosis [39].
2. Overview of the Market
2.1. Treatment options
Symptomatic treatment with acetylcholinesterase inhibitors is 
recommended as a first-line treatment for MG. Pyridostigmine 
is the most widely used drug in this class. Some patients with 
mild disease experience adequate symptom control with this 
class of drugs alone, requiring no further treatment [1]. 
However, in patients with moderate or severe MG, the efficacy 
of these agents is usually limited and/or temporary, requiring 
concomitant use of immunotherapeutic interventions. Side 
effects of acetylcholinesterase inhibitors include nausea, diar-
rhea, abdominal pain, urinary urgency, increased salivation, 
sweating, and/or increased weakness [1,17,40,41].
Many patients with anti-AChR+ MG present with thymus 
pathology [5]. International consensus guidance recommends 
thymectomy in patients with thymoma and in patients 
≤60 years of age with anti-AChR+ antibodies irrespective of thy-
mus pathology [5,42,43]. While differences in regional treatment 
approaches exist, thymectomy may also be considered in select 
patients with ocular symptoms only and, in rare cases, in serone-
gative patients who do not respond to initial treatment [5,17,43].
Oral prednisone, prednisolone, or other glucocorticoids are 
commonly used immunotherapeutic options after first-line ther-
apy and may also be used as alternatives or additions to sympto-
matic and other immunosuppressive treatments initiated as first- 
line therapy [5,17,43]. The benefits of corticosteroid agents for 
patients with MG are well established; however, long-term use 
often leads to side effects such as weight gain, osteoporosis, 
hypertension, diabetes, acne, and mood disorders [17,44]. 
Nonsteroidal immunosuppressive drugs, such as purine inhibitors 
(e.g., azathioprine and mycophenolate mofetil) and the cyclophi-
lins (e.g., cyclosporine and tacrolimus), provide clinical benefit 
without corticosteroid-related adverse effects [17]. However, 
these treatments can cause nausea, hepatic enzyme increases, 
diarrhea, hypertension, leukopenia, and an increased risk of severe 
infections or malignancy, especially with long-term use, as is 
typical in patients with MG [17]. Potential teratogenic side effects 
of some immunosuppressive treatments limit their use in women 
who are or could become pregnant [12,45,46].
The anti-CD20 monoclonal antibody rituximab has emerged 
as a gMG therapy [46]. Although the randomized, placebo- 
controlled BeatMG trial showed no clear benefit of rituximab in 
patients with AChR+ gMG who were receiving steroid treatment 
[47], other studies suggest potential clinical benefit in patients 
with anti-MuSK+ MG who had not responded to standard ther-
apy, as well as in patients with new-onset, non-MuSK+ gMG 
[48–51]; however, more studies are needed to better understand 
the value of this treatment option.
The promise of gMG treatment strategies targeting inhibi-
tion of the complement cascade was affirmed when eculizu-
mab, an intravenous monoclonal antibody that inhibits C5, 
demonstrated efficacy in patients with non-thymomatous 
gMG for whom prior therapy had failed, leading to its approval 
for use in the United States (anti-AChR+ gMG), European Union 
(anti-AChR+ refractory gMG), and Japan (anti-AChR+ gMG with 
symptoms poorly controlled by high-dose intravenous immu-
noglobulin or plasma exchange) in 2017 [52–56]. The eculizu-
mab label contains a warning against life-threatening and fatal 
meningococcal infection, thus requiring vaccination prior to 
use [53,57]. Eculizumab is generally reserved for patients 
whose disease is treatment-resistant, is ineffective for patients 
harboring rare C5 mutations in the eculizumab-binding site, 
and incurs a high financial cost [53,56–58].
Intravenous immunoglobulin (IVIg) and plasma exchange 
(PLEX) are used in patients with treatment-resistant disease or 
as a rescue treatment for myasthenic crisis [43,59]. Their utility 
can be attributed to effects that include complement system 
modulation and neutralization or removal of antibodies and 
cytokines [5]. Both IVIg and PLEX are generally considered 
short-term interventions because of contraindications, treat-
ment risks, lack of long-term efficacy data, and burdensome 
administration [43,59].
The MG treatment pipeline is robust and includes existing 
therapeutic targets with improvement on routes of administra-
tion [60]. In addition, there are multiple agents in development 
that target other components of the complement cascade 
[29,60,61]. Other approaches under investigation seek to reduce 
484 J. F. HOWARD ET AL.
autoantibody production via the fragment crystallizable neona-
tal receptor (FcRn), proteasomes, or proinflammatory cytokines 
and chemokines, or depletion of B and plasma cells via targeting 
of other cluster of differentiation antigens (e.g., anti-CD19) [62].
2.2. Unmet Treatment Needs
Despite current standard-of-care treatment, data from the MG 
Patient Registry, the largest patient-reported database of patients 
with MG, reflect a high degree of disease burden for many patients, 
suggesting a continued need for additional treatment options [6]. 
Suboptimal response to initial therapy or intolerable side effects 
seem to be associated with younger age and female sex [63]. These 
factors may contribute to the higher disease burden experienced 
by these two populations and may be reflective of clinician reluc-
tance to prescribe more aggressive treatment because of 
associated side effects and long-term risks that may disproportio-
nately impact these patients [6]. In a cross-sectional study of 
neurological centers in Japan, patients with MG reported 
decreases in employment or income due to their disease, as well 
as reduced social positivity and activity [7]. In a cross-sectional 
study of Norwegian and Dutch patients with MG, current treat-
ment with non-steroidal immunosuppressive therapies negatively 
impacted health-related QoL [64]. Taken together, these data 
suggest there is room for improvement in patients’ disease- 
related QoL that may be enhanced with novel treatment options.
3. Introduction to Zilucoplan
3.1. Primary Characteristics
Zilucoplan is an investigational, small (3.5 kDa), 15-amino acid 
macrocyclic peptide designed to inhibit terminal complement 
Figure 1. The (A) complement cascade and (B) depiction of the molecular components of a normal vs AChR+ gMG neuromuscular junction and the impact on 
muscle contraction. Graphics are schematic representations and are not true to scale. In panel A, a truncated version of the full complement cascade is presented 
with a focus on specific mechanisms relevant to zilucoplan in AChR+ gMG. ACh binds to AChR on normal postsynaptic membrane folds, allowing for normal 
neuromuscular signaling and muscle contraction. In panel B, autoantibodies against AChR initiate the classical complement cascade, resulting in the deposition of 
MAC on the postsynaptic membrane, damage to the membrane fold structure, and reduction of AChR expression, resulting in attenuated neuromuscular signaling 
and muscle contraction. ACh, acetylcholine; AChR, acetylcholine receptor; AChR+, acetylcholine receptor positive; C[x], complement component [x]; gMG, generalized 
myasthenia gravis; MAC, membrane attack complex; NMJ, neuromuscular junction.
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activation, a consequence of anti-AChR-mediated initiation of 
the complement cascade (Figure 2A; Box 1). Zilucoplan binds 
C5 with high affinity and specificity to prevent downstream 
assembly of the MAC by a dual mechanism: 1) inhibiting the 
cleavage of C5 by C5 convertase into C5a and C5b (Figure 2B) 
and 2) binding to preformed C5b to sterically block interaction 
with C6. Targeting C5 preserves proximal cascade effects 
including C3b-mediated opsonization, C3a inflammatory 
response, and immune complex clearance. Zilucoplan is self- 
administered once daily as a subcutaneous (SC) injection of 
approximately 5 seconds [65].
3.2. Pharmacokinetics and Pharmacodynamics
In a phase 1 multiple-dose study, in which healthy volunteers 
received single doses (0.5 to 4 mg/kg) or multiple, once-daily 
SC administrations of zilucoplan 0.2 mg/kg, plasma concentra-
tions were consistent with the in silico pharmacokinetic mod-
els and between the single- and multiple-dose parts of the 
human study. Exposures were consistent and showed low 
variability across all participants, with maximum plasma con-
centration observed 3 hours postdose [66]. The approximate 
half-life was 7 days across all dose levels [67]. Steady-state 
plasma levels were predicted to be achieved at day 11 at 
a 0.2-mg/kg dose level [66].
The pharmacodynamic profile of zilucoplan was explored in 
the phase 1 single- and multiple-dose groups of healthy 
volunteers using an ex vivo antibody-sensitized sheep red 
blood cell (sRBC) lysis assay [68] to assess the classical pathway 
of complement activation. Inhibition in the hemolysis assay 
(i.e., suppression of complement activity) was rapid and dose- 
dependent, with near-complete inhibition observed approxi-
mately 3 hours postdose [66,67].
These pharmacodynamic results were confirmed in a 12- 
week phase 2 study of patients with gMG, in which 
a zilucoplan 0.3-mg/kg dose resulted in 97% inhibition in the 
sRBC lysis assay (Figure 3). The zilucoplan 0.1-mg/kg dose 
resulted in rapid and consistent, yet submaximal, inhibition 
of sRBC hemolysis at approximately 88% [65]. Furthermore, 
zilucoplan exhibited equipotent binding and inhibition of 
hemolysis induced by C5 variants, including the mutation 
associated with poor response to eculizumab [65,69,70].
3.3. Clinical Efficacy
The efficacy of zilucoplan for the treatment of anti-AChR+ gMG 
was assessed in a 12-week, randomized, double-blind, placebo- 
controlled phase 2 trial (ClinicalTrials.gov identifier: 
NCT03315130) in patients aged 18 to 85 years with a clinically 
confirmed diagnosis of Myasthenia Gravis Foundation of 
America (MGFA) Class II–IVa gMG [70,71], presence of AChR 
autoantibodies, and Quantitative MG (QMG) score [72] of ≥12 
points, with a score of ≥2 on at least four items [65]. Patients were 
stratified based on the screening QMG score (≤17 vs ≥18 points) 
and randomized to receive once-daily SC zilucoplan 0.3 mg/kg 
(n = 15), zilucoplan 0.1 mg/kg (n = 15; however, only 14 received 
at least 1 dose of study drug), or placebo (n = 15) [65]. Patients 
maintained stable doses of standard-of-care treatments, includ-
ing pyridostigmine, corticosteroids, and immunosuppressive 
drugs, throughout the study. The primary and key secondary 
end points were least square means change from baseline to 
week 12 in QMG score and MG-Activities of Daily Living (MG- 
ADL) score [73], respectively. Reductions of at least 3 points on 
the QMG and 2 points on the MG-ADL were considered clinically 
meaningful [74,75]. Additional end points included change from 
baseline to week 12 in the 15-item MG Quality of Life–Revised 
(MG-QoL15r) [76] and MG Composite (MGC) [77] scores and the 
proportion of patients who required rescue therapy with PLEX or 
IVIg. Statistical analyses of the end points used zilucoplan 0.3 mg/ 
kg versus placebo as the primary comparison, and all efficacy 
evaluations were based on a one-sided 0.10 significance 
level [65].
At baseline, patients (N = 44) were considered moder-
ately to severely affected by gMG, with a mean (SD) QMG 
score of 18.8 (4.3), and approximately 60% were classified 
with MGFA Class III or IV gMG. Treatment with zilucoplan 
0.3 mg/kg resulted in rapid, clinically meaningful, and sta-
tistically significant improvements compared with placebo 
in QMG score at 12 weeks (least squares mean [SEM] differ-
ence, –2.8 [1.7]; P = 0.05) and MG-ADL score (–2.3 [1.3]; 
P = 0.04; Figure 4A and 4B; Table 1). Ten of 14 patients 
(71%) in the zilucoplan 0.3-mg/kg group achieved 
a clinically meaningful improvement in QMG score 
(≥3-point decrease). A rapid onset of action was demon-
strated with separation between treatment groups as early 
as 1 week after treatment. Similar trends were observed for 
the MG-QoL15r and MGC scales (Figure 4C and 4D; Table 1) 
[65]. No statistical interaction of the treatment effect of 
zilucoplan 0.3 mg/kg with immunosuppressive therapy, 
IVIg, or PLEX was found for any of the four efficacy scales. 
The zilucoplan 0.1-mg/kg group showed a delayed and less- 
pronounced response than the 0.3-mg/kg group, with sta-
tistically significant differences versus placebo observed for 
the QMG, MG-ADL, and MG-QoL15r end points (Table 1). 
Use of rescue therapy with PLEX or IVIg, administered at the 
investigator’s discretion, was reduced with zilucoplan treat-
ment versus placebo (Table 1) [65].
At the end of 12 weeks, participants from the phase 2 trial 
were eligible to enter an open-label extension period in which 
zilucoplan-treated patients continued at the same dosage and 
placebo recipients were randomized 1:1 to receive once-daily 
zilucoplan 0.3 mg/kg or zilucoplan 0.1 mg/kg [65,78]. Patients 
who received zilucoplan 0.3 mg/kg from the start of the 
double-blind treatment period through week 24 (n = 13) 
experienced sustained reductions from baseline in QMG 
score (mean [SEM] difference, –7.8 [1.3]; Figure 4A) as well as 
in MG-ADL, MG-QoL15r, and MGC scores (Figure 4B–D). 
Further, placebo recipients who crossed over to zilucoplan 
0.3 mg/kg after 12 weeks (n = 7) experienced rapid improve-
ments on all four scales that were sustained at week 24 (Figure 
4). The results of this study supported the 0.3-mg/kg dose that 
is currently under investigation in a pivotal phase 3 study of 
zilucoplan for the treatment of gMG (RAISE; NCT04115293).
3.4. Safety and Tolerability
Zilucoplan was well tolerated in the double-blind, phase 2 con-
trolled trial, with no pattern in treatment-emergent adverse 
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events (TEAEs) observed across treatment groups: zilucoplan 
0.3 mg/kg, 12 (86%) of 14 patients; zilucoplan 0.1 mg/kg, 15 
(100%) of 15 patients; and placebo, 12 (80%) of 15 patients. 
Injection-site reactions occurred in 3 (21%) of 14, 4 (27%) of 15, 
and 2 (13%) of 15 patients who received zilucoplan 0.3 mg/kg, 
zilucoplan 0.1 mg/kg, and placebo, respectively. All injection-site 
reactions in zilucoplan-treated patients were mild. Eight serious 
TEAEs were reported (zilucoplan 0.3 mg/kg, n = 5/14 [36%]; 
placebo, n = 3/15 [20%]), but none were considered study drug 
related. No meningococcal infections, deaths, life-threatening 
adverse events, or anti-zilucoplan antibodies were reported 
[65]. These data were consistent with previous experience in 
other studies [66,67]. No new safety signals were observed dur-
ing the open-label extension study.
3.5. Regulatory Status
In August 2019, the US Food and Drug Administration, which 
defines rare diseases as those that affect fewer than 200,000 
people in the United States, designated zilucoplan as an 
orphan drug for the treatment of gMG [79]. Zilucoplan is 
currently in phase 3 development (NCT04115293) and has 
not been approved for use by any regulatory agency.
4. Conclusion
Anti-AChR+ gMG is a rare, autoantibody-mediated disorder with 
relevant pathogenic contribution of the complement system that 
results in chronic fatigable muscle weakness and reduced QoL. The 
current mainstays of MG treatment include acetylcholinesterase 
inhibitors (e.g., pyridostigmine), immunotherapy with corticoster-
oids, nonsteroidal immunosuppressive drugs (e.g., azathioprine, 
mycophenolate mofetil, cyclosporine, tacrolimus), thymectomy, 
and IVIg/PLEX (mostly used to treat crisis/exacerbations). 
Although none of these treatments addresses the cause of MG, 
immunotherapies can attenuate the underlying immunological 
Figure 2. (A) Activation of the terminal complement cascade in gMG and (B) inhibition by zilucoplan. Graphics are schematic representations and are not true to 
scale. In panel A, cross-linking of AChRs by anti-AChR antibodies initiates the classical complement cascade, leading to cleavage of C5 and assembly of the MAC. In 
panel B, zilucoplan binds C5 at the location corresponding to C5b, thereby inhibiting both the cleavage of C5 and the binding of C6 to pre-formed C5b, thus 
preventing assembly of the MAC. ACh, acetylcholine; AChR, acetylcholine receptor; C[x], complement component [x]; gMG, generalized myasthenia gravis; MAC, 
membrane attack complex; NMJ, neuromuscular junction.
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processes by various mechanisms, leading to a marked improve-
ment in most patients. Nevertheless, some patients continue to 
experience muscle weakness, with subsequent risk of daily func-
tion and QoL impairments, and frequently experience negative 
treatment side effects. Therapeutic targeting of the complement 
cascade is a novel strategy that is based on pathological mechan-
istic rationale, thereby offering the potential for faster and 
improved disease control with increased tolerability and safety as 
compared to current conventional therapy. Zilucoplan, an investi-
gational macrocyclic peptide inhibitor of C5 that is self- 
administered as a once-daily SC injection, produces rapid and 
robust reductions of complement activity and clinically meaningful 
improvements in patient- and clinician-reported disease markers, 
with a favorable safety and tolerability profile based on available 
phase 1 and 2 study results. Expansion of treatment results will be 
forthcoming with data from the ongoing phase 3 clinical trial and 
long-term extensions of the phase 2 and 3 studies.
5. Expert opinion
The available data suggest that zilucoplan may be an important 
advancement in the treatment of gMG. The rapid effect of ziluco-
plan – observed with robust, sustained inhibition of complement 
activity after the first dose and clinical effect after 1 week of once- 
daily treatment – enhances its potential utility. The favorable 
safety and tolerability profile of zilucoplan with few TEAEs in the 
phase 1 and 2 trials supports a potential improvement over 
current standard-of-care treatments, contingent on favorable 
safety and tolerability data in phase 3 and long-term extension 
studies. Zilucoplan may benefit patients (1) whose disease is sub-
optimally controlled; (2) who are considered to have treatment- 
resistant disease; and/or (3) who have intolerable side effects from 
other immunotherapies.
Nearly 29% of the patients treated with zilucoplan 0.3 mg/kg in 
the phase 2 study did not experience clinically meaningful 
improvement on the QMG at week 12. It may be that NMJ damage 
in these patients had progressed such that complement inhibition 
was unable to affect these structural changes. Another potential 
reason for this lack of response is that 12 weeks may not have 
been sufficient for improvement in some of these patients. In the 
REGAIN double-blind and open-label extension study of eculizu-
mab, the percentage of eculizumab-treated patients achieving an 
MGFA post-intervention status of minimal manifestations 
increased from 21% to 46% between weeks 12 and 26 and 
increased further to 53% at week 104, suggesting that response 
may develop over time in some patients with MG [80,81]. Lastly, it 
is possible that a lack of response is related to complement- 
independent effects of autoantibodies such as steric hindrance 
of AChR binding or reduced AChR density at the postsynaptic 
membrane [65].
From a molecular perspective, zilucoplan may hold some 
advantages over other gMG treatments. Zilucoplan is approxi-
mately 40 times smaller than monoclonal antibodies such as 
eculizumab, which may enable greater penetration at the NMJ 
[69]. In addition, unlike therapeutic anti-C5 monoclonal antibodies 
that rely on the FcRn for their pharmacokinetic stability, the pep-
tide composition of zilucoplan should allow for coadministration 
with IVIg or novel FcRn inhibitors that are currently in develop-
ment, without compromising pharmacokinetics.
If phase 2 clinical trial findings can be confirmed in phase 3, 
complement inhibition may emerge as an essential treatment 
modality in the neurology toolbox. It will be important to advance 
understanding and awareness of the role of the complement 
cascade in MG to supplement symptomatic and global immuno-
suppressive therapies with disease-modifying treatments. Positive 
study results for the complement inhibitor eculizumab in the 
Figure 3. Mean inhibition of complement activity by zilucoplan in a 12-week phase 2 study in patients with generalized myasthenia gravis, as measured by ex vivo 
sheep red blood cell hemolysis assay. Figure reproduced with permission from Howard JF Jr, Nowak RJ, Wolfe GI, et al. JAMA Neurol. 2020;77;582–592 [65]. LLOQ, 
lower limit of quantification.
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treatment of gMG have initiated the acceptance of this treatment 
modality, although these data are in the context of treatment- 
resistant disease only: pivotal trial inclusion criteria required 
≥12 months of inadequate symptom control with ≥2 therapies, 
and many eculizumab indications are for the treatment of gMG 
resistant to other treatments, including IVIg and PLEX. Findings 
from the zilucoplan phase 2 study, in which inadequate response 
to prior treatment was not required for inclusion and in which 
there was no statistical interaction of the treatment effect of 
zilucoplan with prior therapies, suggest that the benefits of com-
plement inhibition need not be reserved for patients with 
treatment-resistant disease. Future examination of seronegative 
patients, older patients, patients with severe ocular anti-AChR+ 
MG, and patients receiving IVIg or FcRn inhibitors may further 
expand the populations that could benefit from zilucoplan. It 
stands to reason that introducing complement inhibition earlier 
in the disease process may help prevent architectural damage of 
the NMJ; on the contrary, it is unknown whether complement 
inhibition has the potential to reverse existing architectural 
damage. The rapid onset of complement inhibition and improve-
ment in symptoms with zilucoplan may suggest potential utility as 
a rescue treatment for patients with impending myasthenic crisis. 
Figure 4. Change from baseline through 12 weeks in the double-blind treatment phase [65] and from weeks 12–24 in the open-label extension treatment phase 
[78] in the (A) QMG, (B) MG-ADL, (C) MG-QoL15r, and (D) MGC scales. Error bars denote SEMs of least squares mean in all randomized participants who received at 
least one dose of study drug. Double-blind treatment data were presented in Howard JF Jr, Nowak RJ, Wolfe GI, et al. JAMA Neurol. 2020;77;582–592 [65]; open-label 
treatment data were previously presented at the American Academy of Neurology 2019 Annual Meeting; May 4–10, 2019; Philadelphia, PA [78]. aPrespecified 
significance testing at a one-sided alpha of 0.1 with last-observation-carried-forward analysis of covariance for least squares mean CFB for zilucoplan 0.3 mg/kg vs 
placebo; placebo recipients were re-baselined to zero upon completion of the 12-week double-blind treatment period. CFB, change from baseline; MG-ADL, 
Myasthenia Gravis Activities of Daily Living; MGC, Myasthenia Gravis Composite; MG-QoL15r, 15-item Myasthenia Gravis Quality of Life Revised Scale; QMG, 
Quantitative Myasthenia Gravis; SEM, standard error of the mean.
Table 1. Clinical efficacy outcomes at week 12.
Zilucoplan 0.3 mg/kg vs placebo Zilucoplan 0.1 mg/kg vs placebo
Variable Placebo Zilucoplan 0.3 mg/kg Difference P valuea Zilucoplan 0.1 mg/kg Difference P valuea
N 15 14 NA NA 15 NA NA
QMG –3.2 (1.2) –6.0 (1.2) –2.8 (1.7) 0.05 –5.5 (1.2) –2.3 (1.7) 0.09
MG-ADL –1.1 (0.9) –3.4 (0.9) –2.3 (1.3) 0.04 –3.3 (0.9) –2.2 (1.3) 0.05
MG-QoL15r –2.1 (1.7) –5.9 (1.7) –3.7 (2.4) 0.06 –7.4 (1.7) –5.3 (2.4) 0.02
MGC –3.3 (1.6) –7.4 (1.6) –4.1 (2.2) 0.04 –5.3 (1.5) –2.0 (2.2) 0.19
QMG decrease ≥3, n (%) 8 (53.3) 10 (71.4) NA NS 10 (66.7) NA NS
Rescue received, n (%) 3 (20.0) 0 (0.0) NA NS 1 (6.7) NA NS
Notes: Scale scores and differences are reported as least squares mean (SEM). The table includes data previously presented in Howard JF Jr, Nowak RJ, Wolfe GI, et al. 
JAMA Neurol. 2020;77;582–592 [65]. aOne-sided P values based on a pre-specified significance value of 0.10. 
MG-ADL, Myasthenia Gravis Activities of Daily Living; MGC, Myasthenia Gravis Composite; MG-QoL15r, 15-item Myasthenia Gravis Quality of Life 
Revised Scale; NA, not applicable; NS, not significant; QMG, Quantitative Myasthenia Gravis. 
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At-home, once-daily, SC dosing of zilucoplan should make com-
plement inhibition feasible for most patients; however, the value 
of SC administration may change in the face of novel treatment 
options with alternate routes of administration.
Cost-effectiveness is an essential variable when addressing 
gMG management. Studies on the cost-effectiveness of zilu-
coplan are needed to help physicians, patients, and payer 
systems better assess the value of the drug and evaluate its 
place in gMG treatment.
Data gaps remain in our understanding of pathophysiological 
processes that occur at the NMJ with complement inhibition. It 
will be important to develop companion biomarkers that help 
assess the biologic effects of complement inhibition and the 
individual relevance of the complement system in patients with 
MG. Until then, given their favorable safety profile and rapid 
onset of action, an empiric trial of complement inhibitor therapy 
would be expected to identify most responders within a few 
weeks of initiation, although late responders have also been 
recently identified [80, 81]. Furthermore, it is important to better 
understand whether complement inhibition has effects beyond 
the attenuation of the damage caused by the terminal comple-
ment pathway in MG. Increased risk of serious infection is 
a potential consequence of complement inhibition, as reflected 
by prophylaxis recommendations for eculizumab; however, data 
from patients receiving long-term treatment (≤192 weeks) with 
eculizumab suggest that risk-mitigation strategies remain effec-
tive with continued therapy [53,57,82,83]. Lastly, and as dis-
cussed previously, it is unknown whether complement 
inhibition can reverse complement-mediated NMJ damage 
once established.
Zilucoplan is a first-of-its-kind, novel cyclic peptide tar-
geting the complement cascade, an essential pathogenic 
element of gMG. Provided that phase 3 efficacy and safety 
data are favorable, zilucoplan would be suitable to be used 
early in the treatment sequence, possibly as first-line 
treatment.
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